ZLAB (Zai Lab) Current Deferred Revenue: $0.0 Mil (As of Mar. 2026)


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.41
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Current Deferred Revenue?

Zai Lab ZLAB +2.28% 64 Current Deferred Revenue is $0.0 Mil as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Zai Lab's current deferred revenue for the quarter that ended in Mar. 2026 was $0.0 Mil.

Zai Lab Current Deferred Revenue Related Terms

Zai Lab Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Zai Lab's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Current Deferred Revenue Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZLAB
64GF Score
Zai Lab Ltd ZLAB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.0 Mil mean?
Zai Lab (ZLAB) has a Current Deferred Revenue of $0.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Zai Lab and its competitors.
Is Zai Lab's Current Deferred Revenue too high?
Zai Lab's current Current Deferred Revenue is $0.0 Mil. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Current Deferred Revenue compare to STOK and ADMA?
Zai Lab's Current Deferred Revenue of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Zai Lab and its competitors. Zai Lab's current Current Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.41 — trading 39.2% below its estimated fair value. The current Current Deferred Revenue is $0.0 Mil. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Current Deferred Revenue is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.41 is trading 39.2% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Current Deferred Revenue: $0.0 Mil
  • GF Value™: $30.30 vs. price of $18.41 (39.2% below fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.41
Price
$30.30
GF Value